In-stent restenosis (ISR) remains the primary cause of target lesion failure following
percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion …

Patients with previous myocardial infarction (MI) are at high risk of recurrent MI, stroke, and
cardiovascular death, with a 5-year risk of nearly 40%. Although the highest risk period is …

Two review articles previously published from our working group were dedicated to the
selection of endpoints as well as to reasons for premature stopping of randomized clinical …

Aim In patients with prior myocardial infarction (MI) on aspirin, the addition of ticagrelor
reduces ischaemic risk but increases bleeding risk. The simultaneous assessment of …

Cardiovascular complications in diabetes are the leading causes for high morbidity and
mortality. It has been shown that alteration of purinergic signaling contributes to diabetes …

Aim and hypotheses The THEMIS randomized trial compared ticagrelor plus aspirin versus
placebo plus aspirin for patients with stable coronary artery disease and type 2 diabetes …

Antiplatelet therapy is the cornerstone of antithrombotic prevention in patients with
established atherosclerosis, since it has been proven to reduce coronary, cerebrovascular …

Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or
undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy …

Heart failure with preserved ejection fraction (HFpEF) roughly represents half of the cardiac
failure events in developed countries. The proposed 'systemic microvascular paradigm'has …

Introduction Ticagrelor is an antiplatelet agent acting through direct and reversible
competitive inhibition of the platelet P2Y12 receptor. While the clinical merits of ticagrelor in …